MDGL
NASDAQMadrigal Pharmaceuticals Inc.
Price$553.33+10.50 (+1.93%)
01:30 PM07:45 PM
News · 26 weeks68-58%
2026-01-182026-07-12
Mix3390d
- Other16(48%)
- Insider9(27%)
- SEC Filings7(21%)
- Earnings1(3%)
Latest news
25 items- PRMadrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. The webcast will be available approximately two ho
- PRMadrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP PortfolioReceived two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Building a robust patent estate is a core pillar of
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- PRRibo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHSUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. ((Madrigal, NASDAQ:MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership. This milestone is the result of efficient collaboration and will be followed by immediate initiation of IND-enabling studies to support planned clinical studies. This partnership fully underscores Ribo's and Madrigal's joint commitment to advan
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregat
- INSIDERDirector Taub Rebecca was granted 454 shares, increasing direct ownership by 0.10% to 452,667 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Levy Richard S was granted 454 shares, increasing direct ownership by 2% to 22,469 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Fouse Jacqualyn A was granted 454 shares, increasing direct ownership by 41% to 1,551 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Daly James M was granted 454 shares, increasing direct ownership by 17% to 3,081 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Brennan Daniel J. was granted 404 shares, increasing direct ownership by 42% to 1,371 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- INSIDERDirector Baker Bros. Advisors Lp was granted 1,816 shares (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECSEC Form S-8 filed by Madrigal Pharmaceuticals Inc.S-8 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 1, 2026 to 20 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate,
- PRMadrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026CONSHOHOCKEN, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 on Wednesday, June 10, 2026, at 11:20 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical ne
- INSIDERChief Medical Officer Soergel David sold $516,561 worth of shares (1,042 units at $495.74) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 10,033 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASHGrowing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles associated with cardiovascular risk, including LDL-C, ApoB and Lp(a), in a secondary analysis from the Phase 3 MAESTRO program In patients with well-compensated MASH cirrhosis (F4c), Rezdiffra improved a risk score – ANTICIPATE-NASH – that predicts the probability of experiencing severe liver-related eventsMultiple real-world analyses evaluating the use of Rezdiffra in routine clinical practice demonstrated early and sustained improvements in cardiometabolic parameters, liver-related biomarkers, and live
- INSIDERDirector Levy Richard S sold $2,928,716 worth of shares (5,682 units at $515.44) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 22,015 units (SEC Form 4)4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 15, 2026 to 15 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate, 5
- PRMadrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskSecondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in patients with compensated MASH cirrhosis (F4c) examines improvement in ANTICIPATE-NASH risk scores, a marker for clinically significant portal hypertensionAdditional abstracts focus on early real-world evidence with Rezdiffra and the ability of noninvasive biomarkers to predict fibrosis improvement in patients treated with Rezdiffra CONSHOHOCKEN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeut
- INSIDERChief Medical Officer Soergel David sold $435,420 worth of shares (844 units at $515.90), decreasing direct ownership by 7% to 11,075 units (SEC Form 4) to satisfy tax liability4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
- PRMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as an inducement material to employees' acceptance of employment with the company. The new employees received, in the aggregate, op
- SECSEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
- SECSEC Form 8-K filed by Madrigal Pharmaceuticals Inc.8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
MDGL FAQ
7 questionsWhat does Madrigal Pharmaceuticals Inc. do?
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.Where does MDGL stock trade?
Madrigal Pharmaceuticals Inc. (MDGL) is listed on NASDAQ.What sector and industry is MDGL in?
Madrigal Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Madrigal Pharmaceuticals Inc. go public?
Madrigal Pharmaceuticals Inc. (MDGL) completed its IPO in 2007.What are analysts saying about MDGL?
Madrigal Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-01-28.What companies are similar to MDGL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MDGL side-by-side with any of them on Quantisnow.How can I track MDGL on Quantisnow?
Quantisnow aggregates Madrigal Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MDGL to receive live email and push alerts on every new disclosure.